Journey Medical Corporation (NASDAQ:DERM) Q4 2022 Earnings Call Transcript

I think that goes a long way. And that’s why we believe, again, when we’ve discussed this with our KOLs and other consultants, the early adoption for DFD is going to be quite considerable. So we’re expecting a very quick uptake and that’s how we see us getting to those numbers. So brand or generic, if you have an asset that has tremendous results, you’re going to have a very big home run in the field of dermatology. Anytime you can get close to that $100 million mark, that’s considered a grand slam, again, on these small molecules.

Andrew Fleszar: That’s helpful. And then maybe one follow-up on the efficacy piece of it. I guess what feedback are you hearing specifically from those KOLs and the physician community that gives you confidence that they would prescribe DFD-29 over Oracea if the efficacy holds up in the pivotal study?

Claude Maraoui: Sure. What we did simply is we’ve shared during our due diligence, we have shared all the Phase II data, and we’ve asked them to analyze it, and we’ve given them the messages that we believe we would be able to do once we have an approved label. And the feedback was exactly that, make sure you have a product that’s not just going to be approved going against a placebo. You have to go against the market leader and that’s Oracea. So that’s what the Phase II included fortunately for us, and that’s what we are counting on here in the Phase III study. And secondly, when they looked at all the various adverse events, very comparable. So they’re already familiar with Oracea, they’ve been relatively satisfied with its efficacy.

Now we’re going to be introducing a new indicated product for rosacea specifically that hopefully is getting close to doubling the efficacy. The question is, why wouldn’t they convert over quickly to this brand. And that’s what we heard time and time again. And there’s minocycline doctors, there’s doxycycline doctors. And there’s different classes, right? And a lot of these doctors that we did speak to were the doxycycline, and we were very positive and very pleased with what we were — the feedback that we received. And that really was a key factor in us moving forward in licensing and acquiring this asset.

Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Claude for any closing remarks.

Claude Maraoui: Sure. I just want to thank everyone for their participating in today’s conference call and their interest in Journey Medical. We look forward to sharing our ongoing progress when we report the first quarter results in May. Thanks, and have a good day, everyone.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.